Clinical Trials

70 enrolled

Multiple Myeloma

NCT04133636 2026-03-17

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT05257083 2026-03-17

CARTITUDE-6

759 enrolled

Multiple Myeloma

NCT06353022 2026-03-17

IFm2022-01

103 enrolled

Multiple Myeloma

NCT04181827 2026-03-16

CARTITUDE-4

419 enrolled 10 charts

Multiple Myeloma

NCT03901963 2026-03-13

AURIGA

200 enrolled 12 charts

Multiple Myeloma

NCT04108195 2026-03-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

290 enrolled

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT06577025 2026-03-13

aMMbition

43 enrolled

Multiple Myeloma

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04656951 2026-03-05

GMMG-DADA

67 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05434689 2026-03-05

COMMANDER

80 enrolled

Multiple Myeloma

NCT03589222 2026-02-27

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT04933539 2026-02-27

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

14 enrolled

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT04113018 2026-02-03

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

39 enrolled 16 charts

Multiple Myeloma

NCT05497804 2026-02-03

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT03652064 2026-01-20

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 1 FDA

Multiple Myeloma

NCT05455320 2026-01-16

MonumenTAL-3

864 enrolled

Multiple Myeloma, Recurrence

NCT03447808 2026-01-07

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

15 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04910568 2025-12-24

CAMMA 1

126 enrolled

Multiple Myeloma

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT04009109 2025-12-18

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

79 enrolled

Multiple Myeloma

NCT03290950 2025-12-15

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

75 enrolled

Multiple Myeloma

NCT03346135 2025-12-05

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

31 enrolled

Phase 4 Active not recruiting

Multiple Myeloma

NCT03829371 2025-12-03

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

450 enrolled

Multiple Myeloma

NCT03734198 2025-11-26

IDA53

LymphoidOther hematologic neoplasm

29 enrolled

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05392946 2025-10-29

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Phase 1/2 Active not recruiting

49 enrolled

Multiple Myeloma

NCT03763162 2025-10-24

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT03500445 2025-10-03

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

75 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04071457 2025-09-15

DRAMMATIC

1,100 enrolled

Multiple Myeloma

NCT04497961 2025-09-11

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

95 enrolled

Multiple Myeloma

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

50 enrolled

Multiple Myeloma

NCT05308654 2025-08-14

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

34 enrolled

Multiple Myeloma, Neoplasms

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

401 enrolled

Disease, Multiple Myeloma

NCT04124497 2025-08-08

DPd

45 enrolled

Chromosome 17 deletion, Multiple Myeloma

NCT04635189 2025-08-08

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

28 enrolled

Multiple Myeloma

NCT04052880 2025-07-20

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

17 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04975997 2025-07-10

EXCALIBER-RRMM

864 enrolled

Multiple Myeloma

NCT04775550 2025-07-02

PRISM

61 enrolled

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

24 enrolled 10 charts

Multiple Myeloma

NCT03556332 2025-04-29

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

41 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04922723 2025-04-18

PRIDE

16 enrolled

CNS

Glioblastoma

NCT04166565 2025-04-17

EMN19

41 enrolled